Compare BioNano Genomics Inc (BNGO) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Liberty Global Ltd Class C — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.48B). The key difference: Liberty Global Ltd Class C is far larger — about 254.8× BioNano Genomics Inc's market cap, and Liberty Global Ltd Class C is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | LBTYK | |
|---|---|---|
Market Cap | $13.66M | $3.48B |
Sector | Health | Technology |
52-Week High | $4.92 | $12.67 |
52-Week Low | $1.06 | $9.59 |
Enterprise Value | $16.26M | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
LBTYK trades at $10.13, up 1.4% on the day, amid a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while full-year 2025 showed a net loss of $7.14B despite $4.88B revenue. Positive cash flow trends and the upcoming Ziggo Group spin-off in 2027 are key developments, with analyst sentiment leaning bullish with 69% buy ratings.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside from a discounted valuation, but high losses and competitive pressures pose significant risks. Investors should weigh the sum-of-parts opportunity against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
